Key result
Escitalopram carries a dose-related QTc prolongation risk that differs marginally from citalopram.
Why the study?
The cardiac risks of escitalopram, particularly its potential to prolong the QTc interval and cause torsade de pointes, remain unclear compared to citalopram.
Key points are not available for this paper at this time.
Comparison
Escitalopram vs citalopram
Design
Other
Clinicians should retain QTc caution with escitalopram; Level 5 evidence leaves differential TdP risk open for prospective study.
One should not conclude from the discussion by Lam[1][1] that escitalopram is free of cardiac risks. Citalopram and escitalopram differ marginally in terms of their risk of prolonging the QTc interval sufficient to link to torsade de pointes (TdP). Citalopram and escitalopram each demonstrate a dose
No takes yet. Share an insight, caveat, or question.
Hasnain et al. (2013) studied this question. Escitalopram carries a dose-related risk of QTc prolongation linked to torsade de pointes that differs only marginally from the risk associated with citalopram.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: